VISEN Pharma Executes HK$0.21 Million Share Buyback, Trimming Free Float by 0.008%

Bulletin Express05-20

VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40 to HK$24.88 per share (volume-weighted average: HK$24.41).

Post-transaction, the company’s outstanding share capital (excluding treasury stock) declined marginally to 113.90 million shares from 113.91 million, representing a 0.008% reduction. Treasury shares increased from 15,400 to 24,200, while the total issued share count remained unchanged at 113.93 million.

The repurchases were executed under the mandate approved on 27 June 2025, which allows for up to 11.39 million shares to be bought back. Cumulative repurchases under this mandate now total 24,200 shares, equivalent to 0.02% of the shares outstanding on the mandate date.

A moratorium on issuing new shares or selling treasury shares is in effect until 19 June 2026, in accordance with Hong Kong listing regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168426481?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168426481","market":"hk","top_or_hot":-1,"title":"VISEN Pharma Executes HK$0.21 Million Share Buyback, Trimming Free Float by 0.008%","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40 to HK$24.88 per share (volume-weighted average: HK$24.41).</p>\n<p>Post-transaction, the company’s outstanding share capital (excluding treasury stock) declined marginally to 113.90 million shares from 113.91 million, representing a 0.008% reduction. Treasury shares increased from 15,400 to 24,200, while the total issued share count remained unchanged at 113.93 million.</p>\n<p>The repurchases were executed under the mandate approved on 27 June 2025, which allows for up to 11.39 million shares to be bought back. Cumulative repurchases under this mandate now total 24,200 shares, equivalent to 0.02% of the shares outstanding on the mandate date.</p>\n<p>A moratorium on issuing new shares or selling treasury shares is in effect until 19 June 2026, in accordance with Hong Kong listing regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma Executes HK$0.21 Million Share Buyback, Trimming Free Float by 0.008%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma Executes HK$0.21 Million Share Buyback, Trimming Free Float by 0.008%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-20 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40 to HK$24.88 per share (volume-weighted average: HK$24.41).</p>\n<p>Post-transaction, the company’s outstanding share capital (excluding treasury stock) declined marginally to 113.90 million shares from 113.91 million, representing a 0.008% reduction. Treasury shares increased from 15,400 to 24,200, while the total issued share count remained unchanged at 113.93 million.</p>\n<p>The repurchases were executed under the mandate approved on 27 June 2025, which allows for up to 11.39 million shares to be bought back. Cumulative repurchases under this mandate now total 24,200 shares, equivalent to 0.02% of the shares outstanding on the mandate date.</p>\n<p>A moratorium on issuing new shares or selling treasury shares is in effect until 19 June 2026, in accordance with Hong Kong listing regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1168426481","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168426481","pubTimestamp":1779273789,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"维森制药执行21万港元股份回购，自由流通量削减0.008%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals repurchased 8,800 ordinary shares on 20 May 2026 via on-market transactions on the Hong Kong Stock Exchange, paying an aggregate HK$0.21 million at prices ranging from HK$23.40 to HK$24.88 per share (volume-weighted average: HK$24.41).\nPost-transaction, the company’s outstanding share capital (excluding treasury stock) declined marginally to 113.90 million shares from 113.91 million, representing a 0.008% reduction. Treasury shares increased from 15,400 to 24,200, while the total issued share count remained unchanged at 113.93 million.\nThe repurchases were executed under the mandate approved on 27 June 2025, which allows for up to 11.39 million shares to be bought back. Cumulative repurchases under this mandate now total 24,200 shares, equivalent to 0.02% of the shares outstanding on the mandate date.\nA moratorium on issuing new shares or selling treasury shares is in effect until 19 June 2026, in accordance with Hong Kong listing regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168426481","isCrawlerRequest":true}